Radioligand Therapy

Dr. Keith Crawford, (Director of Clinical Trials and Patient Education, PHEN) discuss the basics of Radioligand Therapy (RLT) and how it is used to treat prostate cancer. Dr. Neil Fleshner (Chair and Professor, Division of Urology, University of Toronto) follows with discussion on the role of precision RLT in treating metastatic castration resistant prostate cancer (mCRPC).


Leave a Reply

Your email address will not be published. Required fields are marked *